Troubled Valeant has started the new year by announcing the sale of some $2.1bn in assets to get funds to hone down its operations and to start easing its debt burden amid allegations of unethical practices.
Valeant Pharmaceuticals International Inc., the embattled Canadian drugmaker under investigation for price gouging, has agreed to sell about $2.1bn in assets to get cash to streamline its businesses and begin easing its $30bn debt burden – and observers believe more sell-offs are on the way.
The first of the two-step move announced Jan. 10 will see Paris-based L'Oreal SA paying Valeant $1.3bn in cash...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US and underlines that it isn’t a comprehensive healthcare fix. Feasibility of MFN pricing and why it may be “catastrophic” to the industry were some of the other topics discussed.
In this week's episode: a look at the likely top drugs in 2030; Lilly CEO advocates US/Europe pricing rebalance; Insmed sees $5bn-plus market for Brinsupri; royalty deals go mainstream; Phase III win sets stage for Epkinly label expansion.
